Protagonist Therapeutics vs Rhythm Pharmaceuticals
PTGX and RYTM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PTGX and RYTM compare
Protagonist Therapeutics is the larger company, worth 1.5 times as much as Rhythm Pharmaceuticals ($9.4B against $6.4B).
Rhythm Pharmaceuticals grew revenue faster over the last twelve months (53.5% versus 34.8% for Protagonist Therapeutics).
Protagonist Therapeutics keeps more of each dollar of sales as profit, with a net margin of 29.4% compared with −85.6% at Rhythm Pharmaceuticals.
Protagonist Therapeutics scores higher on the StockData Score (12 against 5 for Rhythm Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PTGX | RYTM |
|---|---|---|
| Size and price | ||
| Market cap | $9.4B | $6.4B |
| Share price | $144.85 | $92.57 |
| Change, 1 year | 88.9% | −18.7% |
| Change, 5 years | 329% | 566% |
| Beta (5Y) | 0.77 | 1.47 |
| Employees | 132 | 414 |
| StockData Score | ||
| Total score | 12 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 2 | 2 |
| Performance score | 4 (better) | 1 |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 141× | – |
| P/S | 33.2× | 26.6× (better) |
| P/B | 11.1× (better) | 61.9× |
| EV/EBITDA | 143× | – |
| P/FCF | 71.8× | – |
| FCF yield | 1.4% | – |
| Fair value | $36.28 | – |
| Margin of safety | −299% | – |
| Growth | ||
| Revenue growth (TTM) | 34.8% | 53.5% (better) |
| Revenue growth, 5Y average | 10.0% | – |
| Net income growth (TTM) | 59.3% | – |
| EPS growth (TTM) | 47.1% | – |
| Profitability | ||
| Gross margin | – | 89.0% |
| Operating margin | 20.7% (better) | −83.6% |
| Net margin | 29.4% (better) | −85.6% |
| FCF margin | 46.3% | – |
| Return on equity | 11.0% (better) | −451% |
| Return on invested capital | 73.3% | – |
| Financial health | ||
| Debt / equity | 0.00 | 1.03 (better) |
| Interest coverage | – | −10.9× |
| Current ratio | 21.71 (better) | 3.45 |
| Altman Z-score | 128.91 (better) | 12.59 |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 117% | 112% |
| Held by insiders | 1.7% | 1.1% |
| Insider net buying, 12 months | −$86.9M | −$38.6M (better) |
| Superinvestors holding | 1 | 1 |
| Short interest, % of float | 14.7% | 15.8% |
Go deeper
- PTGX stock overview
- PTGX income statement
- PTGX valuation and score
- RYTM stock overview
- RYTM income statement
- RYTM valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.